Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Luca GianniJosé Baselga

Abstract

Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored. This was an international, multicenter, open-label, randomized phase II study. Patients (n = 79) with centrally confirmed HER2-negative metastatic breast cancer were randomly assigned to receive pertuzumab once every 3 weeks with a loading dose of 840 mg followed thereafter by either 420 mg (arm A) or 1,050 mg (arm B). Patients were stratified by country and prior taxane therapy. Of 79 patients who were randomly assigned, 78 were included in the intent-to-treat population. In arm A (n = 41), two patients had partial responses, and 18 patients (44%) experienced stable disease (SD) lasting > or = 12 weeks. In arm B (n = 37), SD was observed in 14 patients (38%). Overall, six of 78 patients responded or had SD > or = 6 months. Pertuzumab was generally well tolerated, and most adverse events were mild to moderate. Decline in left ventricular ...Continue Reading

References

Feb 18, 1998·Current Opinion in Oncology·Z Fan, J Mendelsohn
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Jun 28, 2001·Oncogene·J Mendelsohn, J Baselga
Nov 6, 2001·Oncology·B Leyland-Jones
Mar 22, 2003·Experimental Cell Research·Carlos L Arteaga
Apr 2, 2003·Drugs of Today·Adel M Al-JazzafPeter A Netland
Jul 8, 2003·The Journal of Pathology·Caroline J WittonJohn M S Bartlett
Apr 20, 2004·Cancer Cell·Ali Badache, Nancy E Hynes
Apr 20, 2004·Cancer Cell·Matthew C FranklinMark X Sliwkowski
Feb 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B AgusGwen Fyfe
May 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S N HoldenH I Hurwitz
Jul 30, 2005·Expert Opinion on Biological Therapy·Barbara Burtness
Sep 10, 2005·Cancer Immunology, Immunotherapy : CII·Camellia W AdamsMark X Sliwkowski
Jan 26, 2006·Expert Opinion on Pharmacotherapy·Patricia A TangMalcolm J Moore
Aug 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S GordonBeth Y Karlan
Oct 3, 2006·Journal of the American Academy of Dermatology·Anna Liza C AgeroAllan C Halpern
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johann Sebastian de BonoJohn Graham
Oct 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roy S HerbstBruce E Johnson
Jul 4, 2008·Annals of the New York Academy of Sciences·Simone Diermeier-DaucherGero Brockhoff

❮ Previous
Next ❯

Citations

Jul 12, 2012·Breast Cancer Research and Treatment·Aaron M DruckerMario E Lacouture
Jul 25, 2013·Advances in Therapy·Leticia De Mattos-Arruda, Javier Cortes
Dec 15, 2012·CNS Drugs·Rupert BartschMatthias Preusser
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Jun 8, 2011·Nature Reviews. Gastroenterology & Hepatology·Lorenzo FornaroAlfredo Falcone
Dec 14, 2011·The New England Journal of Medicine·William J Gradishar
Jun 15, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LenihanJ Baselga
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M CapelanM J Piccart-Gebhart
Jan 10, 2013·Journal of the National Cancer Institute·Giampaolo Bianchini, Luca Gianni
Sep 14, 2012·Therapeutic Advances in Gastroenterology·Alicia F C Okines, David Cunningham
May 6, 2011·The Oncologist·Thehang LuuGeorge Somlo
Dec 4, 2012·International Journal of Molecular Sciences·Anne-Sophie Hervent, Gilles W De Keulenaer
Oct 24, 2013·World Journal of Gastroenterology : WJG·Michael LuisRamon Andrade de Mello
Jun 30, 2011·Indian Journal of Pharmacology·Radha MunagalaRamesh C Gupta
Oct 2, 2013·Indian Journal of Pharmaceutical Sciences·Anjana Mohan, S Ponnusankar
Oct 12, 2013·World Journal of Gastroenterology : WJG·Ramon Andrade de MelloAntónio Araújo
Jun 22, 2012·Expert Review of Anticancer Therapy·Jose Perez-GarciaJavier Cortes
Nov 30, 2011·Expert Opinion on Emerging Drugs·Cagatay ArslanOmer Dizdar
Dec 1, 2015·Expert Opinion on Biological Therapy·Do-Youn Oh, Yung-Jue Bang
Aug 27, 2015·Expert Opinion on Drug Metabolism & Toxicology·Andrea RoccaDino Amadori
Jan 7, 2011·Expert Opinion on Pharmacotherapy·Elena GeunaFilippo Montemurro
Jan 11, 2012·Expert Opinion on Investigational Drugs·Giuseppe CuriglianoAron Goldhirsch
Aug 22, 2015·Expert Opinion on Drug Metabolism & Toxicology·Laure-Anne TeuwenLuc Dirix
Mar 28, 2013·Expert Opinion on Biological Therapy·Ciara C O'Sullivan, Sandra M Swain
Nov 26, 2010·Expert Opinion on Drug Safety·Robyn J MacFarlane, Karen A Gelmon
May 23, 2013·Current Medical Research and Opinion·Mehmet A N SendurKadri Altundag
Sep 8, 2012·Current Medical Research and Opinion·Mehmet A N SendurKadri Altundag
Jun 13, 2014·Cancer Investigation·Filipa Lynce, Sandra M Swain
Aug 7, 2013·Pharmacotherapy·Stephanie J MalenfantChad M Barnett
Mar 12, 2015·Future Oncology·Shaheenah Dawood, Bhawna Sirohi
Jan 13, 2015·Future Oncology·Mehmet A N SendurKadri Altundag
Mar 17, 2016·Expert Opinion on Drug Safety·Jennifer Gao, Sandra M Swain
Feb 2, 2012·International Journal of Breast Cancer·Gabriel L Fiszman, María A Jasnis
Oct 3, 2008·Journal of Hematology & Oncology·David Chu, Janice Lu
Nov 6, 2010·MAbs·Janice M Reichert
Jul 4, 2012·Clinical Oncology : a Journal of the Royal College of Radiologists·M FralickE Amir
Jul 3, 2013·Clinical Breast Cancer·Flora ZagouriTheodora Psaltopoulou
Apr 8, 2017·Expert Opinion on Investigational Drugs·James N GersonIgor Astsaturov
May 16, 2014·Current Opinion in Oncology·Jean A Klastersky
Jun 4, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio C Wolff
Jul 12, 2017·Expert Opinion on Drug Safety·Samuel MartelEvandro De Azambuja

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

© 2021 Meta ULC. All rights reserved